Cipher's CEO, Craig Mull, and President of U.S. Operations, Bryan Jacobs, have discussed their future aspirations for Cipher post-Natroba acquisition in a recent interview with Planet Microcap.
Great analysis here and in your operating income piece. What are your thoughts on Moberg's announcement of downgraded expected efficacy for MOB-015 in their Phase 3 North America trial?
This is great as always.
Thank you Dean. Appreciate your continued support and readership.
Great analysis here and in your operating income piece. What are your thoughts on Moberg's announcement of downgraded expected efficacy for MOB-015 in their Phase 3 North America trial?